---
title: 'A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and
  Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents
  with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY
  study'
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38589856/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240409180714&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Biliary tract cancers (BTCs) are rare and lethal cancers,
  with a 5-year survival inferior to 20%(1-3). The only potential curative treatment
  is surgical resection. However, despite complex surgical procedures that have a
  remarkable risk of postoperative morbidity and mortality, the 5-year survival rate
  after radical surgery (R0) is 20-40% and recurrence rates are up to ~ 75%(4-6).
  Up to ~ 40% of patients relapse within 12 months after resection, and half of these
  patient will ...'
disable_comments: true
---
BACKGROUND: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1-3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20-40% and recurrence rates are up to ~ 75%(4-6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will ...